OUR SERVICES
01
Disease Modeling
Emulating Human Diseases: Adopting organ-on-chip technology to create accurate models of neuronal diseases.
​
Human-Relevant Data: Using human-derived cells and proprietary technology to mimic the complexity of the nervous system.
​
Creating Solutions: developing novel deseases models to address specific neurological conditions, allowing for targeted research and development.
02
Target Validation
Biological Relevance: Ensuring potential drug targets are biologically relevant by testing them in a more realistic 3D environment.
​
Throughput: Accelerating the validation process by higher throughput screening capabilities.
​
Predictability: Lowering the risk of late-stage clinical trial failures by early validation of promising new targets.
03
Efficacy and Safety Testing
Safety: Predicting adverse responses to new chemical entities in a more physiologically relevant environment than conventional 2D methods.
​
Early Detection: Identifying potential efficacy issues or neurotoxic effects at an early stage in the development cycle.
​
Regulatory Confidence: Providing robust data to support regulatory submissions and enhance confidence in safety profiles.
TECHNOLOGY
3D Models
Our models incorporate cells from both the central and peripheral nervous systems, including:​​
-
Matrigel-embedded dissociated cells
Neurons and glial cells, obtained from either primary tissues or human-derived iPS cells, are embedded in biomimetic hydrogel matrices and microfluidic structures with specific 3D geometries. Morphological and electrophysiological data are collected to assess functional differentiation and synaptic activity.
-
Self-aggregated 3D neuronal structures
These structures form through the spontaneous aggregation of iPSC-derived cells into spheroids or brain organoids, depending on the differentiation protocols employed. Containing various types of neurons and glial cells, these models enable the creation of disease-specific systems and the assessment of their modulation by potential new therapeutics.
-
Innervation models
Designed to study the integration of cells from the central or peripheral nervous system into target tissues or organoids, these models facilitate the investigation of genetic disease mechanisms, synaptic connectivity, axonal outgrowth, and functional interactions between neurons and their surrounding tissue targets.
INNOVATION
Unique Features
Usability
PLATFORM
ABOUT US
AxCellerate emerged as a spin-off from the European NEUROCHIP project, developed within the Eurostars program through the collaboration of FEMTOprint SA, a Swiss high-tech company, and NMI Natural and Medical Sciences Institute, a German research institute specializing in innovative in vitro assays for life sciences.
AxCellerate’s technology leverages the expertise of these partners in developing an innovative Brain-on-a-Chip (BoC), an advanced system for culturing, analyzing, and monitoring brain organoids with unmatched biological relevance.
MISSION
AxCellerate is committed to transforming pharmaceutical research by delivering cutting-edge solutions that enhance drug discovery while significantly reducing reliance on animal models, fully embracing the advancements enabled by the FDA Modernization Act 2.0.
VISION
We envision a future where pharmaceutical research is driven by ethical, sustainable, and highly efficient approaches, accelerating the development of new treatments for neurological disorders.
VALUES
Innovation, passion for science, ethics, sustainability, social impact, collaboration.
OUR TEAM
At AxCellerate, we are a team of passionate professionals from diverse backgrounds, driven by a shared commitment to advancing new treatments for neurodegenerative disorders. Our mission goes beyond science—we aim to improve lives, empower researchers, and contribute to a healthier future for patients, families, and society as a whole.
MEDIA
In our media section, you can find our news, paper, images, etc...
Stay tuned and discover more about our project and AxCellerate's progress.
INNo-CHIP'S
PROJECT
AxCellerate is part of the INNo-CHIP consortium, funded by the Interreg Italia-Svizzera program, aimed at enhancing the competitiveness of biomedical companies through organ-on-chip (OoC) technology. The project accelerates R&D, reduces experimentation costs, and improves research outcomes.
Led by EURAC Research, the consortium includes NOI Tech Park, FEMTOprint SA, AxCellerate Sagl, and the Life Sciences Competence Center Ticino, working to establish a cross-border biomedical cluster. INNo-CHIP focuses on developing high-fidelity OoC models to advance preclinical research, with a key output being an innovative system.
Total budget (EUR): 1'045'771
Swiss contribution (CHF): 260'000
